Beyond COX inhibition, novel sulindac analogs such as sulindac sulfide amide (SSA; a N,N-dimethylethyl amine derivative of SS) exhibit anti-tumor activity through inhibition of the Akt (PKB)/mechanistic target of rapamycin (mTOR) pathway [14]. This evidence concerns the gene AKT1 and neoplasm.